Safety and Efficacy of an Oxytocin Gel and an Equivalent Gel but Without Hormonal Ingredients (Vagivital^® Gel) in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy: A Randomized, Double-Blind Controlled Study

References

• Iosif CS, Bekassy Z. Prevalence of genito-urinary symptoms in the late menopause. Acta Obstet Gynecol Scand. 1984;63:257–260. doi:10.3109/00016348409155509
   PubMed Web of Science ®Google Scholar
• Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;2016:Cd001500. doi:10.1002/14651858.CD001500.pub3
   PubMed Web of Science ®Google Scholar
• Henriksson L, Stjernquist M, Boquist L, Cedergren I, Selinus I. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol-releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol. 1996;174:85–92. doi:10.1016/s0002-9378(96)70378-2
   PubMed Web of Science ®Google Scholar
• Caillouette JC, Sharp CF Jr, Zimmerman GJ, Roy S. Vaginal pH as a marker for bacterial pathogens and menopausal status. Am J Obstet Gynecol. 1997;176:1270–1275; discussion 1275–1277. doi:10.1016/s0002-9378(97)70345-4
   Web of Science ®Google Scholar
• Bachmann GA. The clinical platform for the 17beta-estradiol vaginal releasing ring. Am J Obstet Gynecol. 1998;178:S257–S260. doi:10.1016/s0002-9378(98)70558-7
   PubMed Web of Science ®Google Scholar
• Grady D. Clinical practice. Management of menopausal symptoms. N Engl J Med. 2006;355:2338–2347. doi:10.1056/NEJMcp054015
   PubMed Web of Science ®Google Scholar
• Cano A, Estévez J, Usandizaga R, et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal Phase III study. Menopause. 2012;19:1130–1139. doi:10.1097/gme.0b013e3182518e9a
   PubMed Web of Science ®Google Scholar
• Freedman M, Kaunitz AM, Reape KZ, Hait H, Shu H. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. Menopause. 2009;16:735–741. doi:10.1097/gme.0b013e318199e734
   PubMed Web of Science ®Google Scholar
• Fernandes T, Costa-Paiva LH, Pedro AO, Baccaro LFC, Pinto-Neto AM. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on vaginal atrophy: a randomized controlled trial. Menopause. 2016;23(7):792–798. doi:10.1097/gme.0000000000000613
   PubMed Web of Science ®Google Scholar
• Kallak TK, Uvnäs-Moberg K. Oxytocin stimulates cell proliferation in vaginal cell line Vk2E6E7. Post Reprod Health. 2017;23:6–12. doi:10.1177/2053369117693148
   PubMedGoogle Scholar
• Uvnas-Moberg K, Petersson M. [Oxytocin, a mediator of anti-stress, well-being, social interaction, growth and healing] [Original text in German]. Z Psychosom Med Psychother. 2005;51:57–80. doi:10.13109/zptm.2005.51.1.57
   PubMed Web of Science ®Google Scholar
• Al-Saqi SH, Jonasson AF, Naessén T, Uvnäs-Moberg K. Oxytocin improves cytological and histological profiles of vaginal atrophy in postmenopausal women. Post Reprod Health. 2016;22:25–33. doi:10.1177/2053369116629042
   PubMedGoogle Scholar
• Al-Saqi SH, Uvnäs-Moberg K, Jonasson AF. Intravaginally applied oxytocin improves post-menopausal vaginal atrophy. Post Reprod Health. 2015;21:88–97. doi:10.1177/2053369115577328
   PubMedGoogle Scholar
• Torky HA, Taha A, Marie H, et al. Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial. Climacteric. 2018;21:174–178. doi:10.1080/13697137.2017.1421924
   PubMed Web of Science ®Google Scholar
• Ghorbani Z, Mirghafourvand M. The efficacy and safety of intravaginal oxytocin on vaginal atrophy: A systematic review. Post Reprod Health. 2020;2053369120946645. doi:10.1177/2053369120946645.
   Google Scholar
• Society NAM. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20:888–902; quiz 903–884. doi:10.1097/GME.0b013e3182a122c2
   Web of Science ®Google Scholar
• 1177 Vårdguiden. Klimakteriebesvär [Health Care Guide. Menopausal Symptoms]; 2017. Available from: https://www.1177.se/Fakta-och-rad/Sjukdomar/Klimakteriebesvar1/. Accessed January 12, 2018.
   Google Scholar
• Ayehunie S, Wang YY, Landry T, Bogojevic S, Cone RA. Hyperosmolal vaginal lubricants markedly reduce epithelial barrier properties in a three-dimensional vaginal epithelium model. Toxicol Rep. 2018;5:134–140. doi:10.1016/j.toxrep.2017.12.011
   PubMed Web of Science ®Google Scholar
• Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016;19:151–161. doi:10.3109/13697137.2015.1124259
   PubMed Web of Science ®Google Scholar
• Lima SM, Bernardo BFA, Yamada SS, et al. Effects of Glycine max (L.) Merr. soy isoflavone vaginal gel on epithelium morphology and estrogen receptor expression in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled trial. Maturitas. 2014;78(3):205–211. doi:10.1016/j.maturitas.2014.04.007
   PubMed Web of Science ®Google Scholar
• Jokar A, Davari T, Asadi N, Ahmadi F, Foruhari S. Comparison of the hyaluronic acid vaginal cream and conjugated estrogen used in treatment of vaginal atrophy of menopause women: a randomized controlled clinical trial. Int J Community Based Nurs Midwifery. 2016;4:69–78.
   PubMedGoogle Scholar
• Lima SMRR, Yamada SS, Reis BF, et al. Effective treatment of vaginal atrophy with isoflavone vaginal gel. Maturitas. 2013;74(3):252–258. doi:10.1016/j.maturitas.2012.11.012
   Web of Science ®Google Scholar
• Vagifem. Vagifem® (estradiol vaginal inserts) 10 mcg; 2017. Available from: https://www.vagifem.com/. Accessed July 18, 2017.
   Google Scholar
• Vagitocin [Investigator’s Brochure] Edition 7.0.; Peptonic Medical. March 2016.
   Google Scholar